公开(公告)号：US20060002999A1

公开(公告)日：2006-01-05

申请号：US11155319

申请日：2005-06-16

申请人： Yan Yang ,  Rajiv Janjikhel ,  Niranjan Rao ,  Antonia Periclou ,  Wattanaporn Abramowitz ,  Mahendra Dedhiya ,  Erhard Seiller ,  Bernhard Hauptmeier

发明人： Yan Yang ,  Rajiv Janjikhel ,  Niranjan Rao ,  Antonia Periclou ,  Wattanaporn Abramowitz ,  Mahendra Dedhiya ,  Erhard Seiller ,  Bernhard Hauptmeier

IPC分类号： A61K9/20 ,  A61K31/13

CPC分类号： A61K31/13 ,  A61K9/28 ,  A61K9/2846 ,  A61K9/2866 ,  A61K47/38 ,  Y02A50/411

摘要： The present invention relates to an immediate release solid oral dosage form containing 1-aminocyclohexanes, preferably memantine or neramexane, and optionally a pharmaceutically acceptable coating, wherein the active ingredient exhibits dose proportionality and is released at a dissolution rate of more than about 80% within about the first 60 minutes following entry of said form into a use environment. The dosage form is direct compressed and has a hardness within the range of between about 3 and about 40 Kp, exhibits an average Tmax within the range of about 2 to about 8 hours with an active ingredient load within the range of about 2.5 to about 150 mg. The formulation allows for dose-proportional compositions for once daily or b.i.d. dosing, while maintaining a steady average range of Tmax.

公开(公告)号：US20060198884A1

公开(公告)日：2006-09-07

申请号：US11304976

申请日：2005-12-14

申请人： Yan Yang ,  Rajiv Janjikhel ,  Niranjan Rao ,  Antonia Periclou ,  Wattanaporn Abramowitz ,  Mahendra Dedhiya ,  Erhard Seiller ,  Bernhard Hauptmeier

发明人： Yan Yang ,  Rajiv Janjikhel ,  Niranjan Rao ,  Antonia Periclou ,  Wattanaporn Abramowitz ,  Mahendra Dedhiya ,  Erhard Seiller ,  Bernhard Hauptmeier

IPC分类号： A61K31/13 ,  A61K9/20

CPC分类号： A61K31/13 ,  A61K9/28 ,  A61K9/2846 ,  A61K9/2866 ,  A61K47/38 ,  Y02A50/411

摘要： The present invention relates to an immediate release solid oral dosage form containing 1-aminocyclohexanes, preferably memantine or neramexane, and optionally a pharmaceutically acceptable coating, wherein the active ingredient exhibits dose proportionality and is released at a dissolution rate of more than about 80% within about the first 60 minutes following entry of said form into a use environment. The dosage form is direct compressed and has a hardness within the range of between about 3 and about 40 Kp, exhibits an average Tmax within the range of about 2 to about 8 hours with an active ingredient load within the range of about 2.5 to about 150 mg. The formulation allows for dose-proportional compositions for once daily or b.i.d. dosing, while maintaining a steady average range of Tmax.

摘要翻译： 本发明涉及含有1-氨基环己烷，优选美金刚或奈拉美生和任选的药学上可接受的包衣的立即释放的固体口服剂型，其中活性成分表现出剂量比例，并以大于约80％的溶解速率释放 大约在所述表格进入使用环境后的前60分钟。 该剂型是直接压制的并且具有在约3至约40Kp范围内的硬度，在约2至约8小时的范围内显示平均T max max，活性成分负载在 约2.5至约150mg的范围。 该制剂允许剂量比例组合物每天一次或b.i.d。 同时保持T max的稳定平均范围。

公开(公告)号：US20110236439A1

公开(公告)日：2011-09-29

申请号：US13134467

申请日：2011-06-08

申请人： Yan Yang ,  Rajiv Janjikhel ,  Niranjan Rao ,  Antonia Periclou ,  Wattanaporn Abramowitz ,  Mahendra G. Dedhiya ,  Erhard Seiller ,  Bernhard Hauptmeier

发明人： Yan Yang ,  Rajiv Janjikhel ,  Niranjan Rao ,  Antonia Periclou ,  Wattanaporn Abramowitz ,  Mahendra G. Dedhiya ,  Erhard Seiller ,  Bernhard Hauptmeier

IPC分类号： A61K9/00 ,  A61K31/13 ,  A61K31/205 ,  A61P25/28 ,  A61P25/16 ,  A61P25/04 ,  A61P25/08 ,  A61P27/06 ,  A61P25/24 ,  A61P31/14 ,  A61P33/06 ,  A61P1/16 ,  A61P25/00

CPC分类号： A61K31/13 ,  A61K9/28 ,  A61K9/2846 ,  A61K9/2866 ,  A61K47/38 ,  Y02A50/411

摘要： The present invention relates to an immediate release solid oral dosage form containing 1-aminocyclohexanes, preferably memantine or neramexane, and optionally a pharmaceutically acceptable coating, wherein the active ingredient exhibits dose proportionality and is released at a dissolution rate of more than about 80% within about the first 60 minutes following entry of said form into a use environment. The dosage form is direct compressed and has a hardness within the range of between about 3 and about 40 Kp, exhibits an average Tmax within the range of about 2 to about 8 hours with an active ingredient load within the range of about 2.5 to about 150 mg. The formulation allows for dose-proportional compositions for once daily or b.i.d. dosing, while maintaining a steady average range of Tmax.

摘要翻译： 本发明涉及含有1-氨基环己烷，优选美金刚或奈拉美生和任选的药学上可接受的包衣的立即释放的固体口服剂型，其中活性成分表现出剂量比例，并以大于约80％的溶解速率释放 大约在所述表格进入使用环境后的前60分钟。 剂型是直接压制的并且硬度在约3至约40Kp之间的范围内，平均Tmax在约2至约8小时的范围内，活性成分负载在约2.5至约150的范围内 mg。 该制剂允许剂量比例组合物每天一次或b.i.d。 同时保持Tmax的稳定平均范围。

公开(公告)号：US20100028427A1

公开(公告)日：2010-02-04

申请号：US12410224

申请日：2009-03-24

申请人： Yan Yang ,  Rajiv Janjikhel ,  Niranjan Rao ,  Antonia Periclou ,  Wattanaporn Abramowitz ,  Mahendra G. Dedhiya ,  Erhard Seiller ,  Bernhard Hauptmeier

发明人： Yan Yang ,  Rajiv Janjikhel ,  Niranjan Rao ,  Antonia Periclou ,  Wattanaporn Abramowitz ,  Mahendra G. Dedhiya ,  Erhard Seiller ,  Bernhard Hauptmeier

IPC分类号： A61K9/22 ,  A61K31/13

CPC分类号： A61K31/13 ,  A61K9/28 ,  A61K9/2846 ,  A61K9/2866 ,  A61K47/38 ,  Y02A50/411

摘要： The present invention relates to an immediate release solid oral dosage form containing 1-aminocyclohexanes, preferably memantine or neramexane, and optionally a pharmaceutically acceptable coating, wherein the active ingredient exhibits dose proportionality and is released at a dissolution rate of more than about 80% within about the first 60 minutes following entry of said form into a use environment. The dosage form is direct compressed and has a hardness within the range of between about 3 and about 40 Kp, exhibits an average Tmax within the range of about 2 to about 8 hours with an active ingredient load within the range of about 2.5 to about 150 mg. The formulation allows for dose-proportional compositions for once daily or b.i.d. dosing, while maintaining a steady average range of Tmax.

摘要翻译： 本发明涉及含有1-氨基环己烷，优选美金刚或奈拉美生和任选的药学上可接受的包衣的立即释放的固体口服剂型，其中活性成分表现出剂量比例，并以大于约80％的溶解速率释放 大约在所述表格进入使用环境后的前60分钟。 剂型是直接压制的并且硬度在约3至约40Kp之间的范围内，平均Tmax在约2至约8小时的范围内，活性成分负载在约2.5至约150的范围内 mg。 该制剂允许剂量比例组合物每天一次或b.i.d。 同时保持Tmax的稳定平均范围。

公开(公告)号：US08834924B2

公开(公告)日：2014-09-16

申请号：US13134467

申请日：2011-06-08

申请人： Yan Yang ,  Rajiv Janjikhel ,  Niranjan Rao ,  Antonia Periclou ,  Wattanaporn Abramowitz ,  Mahendra G. Dedhiya ,  Erhard Seiller ,  Bernhard Hauptmeier

发明人： Yan Yang ,  Rajiv Janjikhel ,  Niranjan Rao ,  Antonia Periclou ,  Wattanaporn Abramowitz ,  Mahendra G. Dedhiya ,  Erhard Seiller ,  Bernhard Hauptmeier

IPC分类号： A61K9/20 ,  A61K9/28 ,  A61K31/13

CPC分类号： A61K31/13 ,  A61K9/28 ,  A61K9/2846 ,  A61K9/2866 ,  A61K47/38 ,  Y02A50/411

摘要： The present invention relates to an immediate release solid oral dosage form containing 1-aminocyclohexanes, preferably memantine or neramexane, and optionally a pharmaceutically acceptable coating, wherein the active ingredient exhibits dose proportionality and is released at a dissolution rate of more than about 80% within about the first 60 minutes following entry of said form into a use environment. The dosage form is direct compressed and has a hardness within the range of between about 3 and about 40 Kp, exhibits an average Tmax within the range of about 2 to about 8 hours with an active ingredient load within the range of about 2.5 to about 150 mg. The formulation allows for dose-proportional compositions for once daily or b.i.d. dosing, while maintaining a steady average range of Tmax.

摘要翻译： 本发明涉及含有1-氨基环己烷，优选美金刚或奈拉美生和任选的药学上可接受的包衣的立即释放的固体口服剂型，其中活性成分表现出剂量比例，并以大于约80％的溶解速率释放 大约在所述表格进入使用环境后的前60分钟。 剂型是直接压制的并且硬度在约3至约40Kp之间的范围内，平均Tmax在约2至约8小时的范围内，活性成分负载在约2.5至约150的范围内 mg。 该制剂允许剂量比例组合物每天一次或b.i.d。 同时保持Tmax的稳定平均范围。

公开(公告)号：US20070270500A1

公开(公告)日：2007-11-22

申请号：US10578765

申请日：2004-11-05

申请人： Mahendra Dedhiya ,  Shashank Mahashabde ,  Yan Yang ,  Anshu Goel ,  Erhard Seiller ,  Bernhard Hauptmeier

发明人： Mahendra Dedhiya ,  Shashank Mahashabde ,  Yan Yang ,  Anshu Goel ,  Erhard Seiller ,  Bernhard Hauptmeier

IPC分类号： A61K31/136 ,  A61K31/13 ,  A61P25/00

CPC分类号： A61K31/13 ,  A61K9/0063 ,  Y02A50/411

摘要： The invention is directed to formulations of pharmaceutical compounds, such as the Cyclohexylamines and Aminoadamantanes which have antimicrobial properties. In particular, it is directed to aqueous based formulations with reduced amounts of preservatives which allow safe and convenient administration and flexible dosing and which, in the case of oral formulations, are easy to swallow. Optionally, the compositions contain components that provide the requisite stability and shelf life while reducing or avoiding incrustation of the composition around the container closure which leads to leaks and difficulty in opening the container.

摘要翻译： 本发明涉及药物化合物的制剂，例如具有抗微生物性质的环己胺和氨基金刚烷。 特别地，其涉及具有减少量的防腐剂的含水基制剂，其允许安全和方便的施用和柔性给药，并且在口服制剂的情况下，易于吞咽。 任选地，组合物包含提供必要的稳定性和保质期的组分，同时减少或避免组合物围绕容器封闭物的结垢，这导致泄漏和难以打开容器。

公开(公告)号：US20060165789A1

公开(公告)日：2006-07-27

申请号：US11223493

申请日：2005-09-09

申请人： Wattanaporn Abramowitz ,  Ram Kapil ,  Todd Riccobene ,  Mahendra Dedhiya ,  Yan Yang ,  Anil Chhettry

发明人： Wattanaporn Abramowitz ,  Ram Kapil ,  Todd Riccobene ,  Mahendra Dedhiya ,  Yan Yang ,  Anil Chhettry

IPC分类号： A61K31/445 ,  A61K9/22

CPC分类号： A61K9/5078 ,  A61K9/2077 ,  A61K31/445

摘要： Pursuant to the present invention, it has been found that a modified release composition containing the low permeability and poor solubility drug, lercanidipine, may be prepared which provides for therapeutically effective plasma concentrations of lercanidipine for a period of about 20 to about 25 hours. The modified release composition of the present invention provides modified release of lercanidipine independent of pH and therefore provides release of lercanidipine even upon exposure to the low pH use environments, such as gastric fluid.

摘要翻译： 根据本发明，已经发现，可以制备含有低渗透性和不良溶解性药物氯卡地平的改进释放组合物，其提供氯卡地平治疗有效的血浆浓度约20至约25小时。 本发明的改性释放组合物提供了独立于pH的氯卡地平的改进释放，因此即使在暴露于低pH使用环境（例如胃液）的情况下也能释放氯卡地平。

公开(公告)号：US20120238631A1

公开(公告)日：2012-09-20

申请号：US13456751

申请日：2012-04-26

申请人： Mahendra G. Dedhiya ,  Shashank Mahashabde ,  Yan Yang ,  Anshu Goel ,  Erhard Seiller ,  Bernhard Hauptmeier

发明人： Mahendra G. Dedhiya ,  Shashank Mahashabde ,  Yan Yang ,  Anshu Goel ,  Erhard Seiller ,  Bernhard Hauptmeier

IPC分类号： A61K31/13 ,  A61P25/00 ,  A61P31/00

CPC分类号： A61K31/13 ,  A61K9/0063 ,  Y02A50/411

摘要： The invention is directed to formulations of pharmaceutical compounds, such as the Cyclohexylamines and Aminoadamantanes which have antimicrobial properties. In particular, it is directed to aqueous based formulations with reduced amounts of preservatives which allow safe and convenient administration and flexible dosing and which, in the case of oral formulations, are easy to swallow. Optionally, the compositions contain components that provide the requisite stability and shelf life while reducing or avoiding incrustation of the composition around the container closure which leads to leaks and difficulty in opening the container.

摘要翻译： 本发明涉及药物化合物的制剂，例如具有抗微生物性质的环己胺和氨基金刚烷。 特别地，其涉及具有减少量的防腐剂的含水基制剂，其允许安全和方便的施用和柔性给药，并且在口服制剂的情况下，易于吞咽。 任选地，组合物包含提供必要的稳定性和保质期的组分，同时减少或避免组合物围绕容器封闭物的结垢，这导致泄漏和难以打开容器。

公开(公告)号：US20100035995A1

公开(公告)日：2010-02-11

申请号：US12587885

申请日：2009-10-14

申请人： Mahendra G. Dedhiya ,  Shashank Mahashabde ,  Yan Yang ,  Anshu Goel ,  Erhard Seiller ,  Bernhard Hauptmeier

发明人： Mahendra G. Dedhiya ,  Shashank Mahashabde ,  Yan Yang ,  Anshu Goel ,  Erhard Seiller ,  Bernhard Hauptmeier

IPC分类号： A61K31/13

CPC分类号： A61K31/13 ,  A61K9/0063 ,  Y02A50/411

摘要： The invention is directed to formulations of pharmaceutical compounds, such as the Cyclohexylamines and Aminoadamantanes which have antimicrobial properties. In particular, it is directed to aqueous based formulations with reduced amounts of preservatives which allow safe and convenient administration and flexible dosing and which, in the case of oral formulations, are easy to swallow. Optionally, the compositions contain components that provide the requisite stability and shelf life while reducing or avoiding incrustation of the composition around the container closure which leads to leaks and difficulty in opening the container.

摘要翻译： 本发明涉及药物化合物的制剂，例如具有抗微生物性质的环己胺和氨基金刚烷。 特别地，其涉及具有减少量的防腐剂的含水基制剂，其允许安全和方便的施用和柔性给药，并且在口服制剂的情况下，易于吞咽。 任选地，组合物包含提供必要的稳定性和保质期的组分，同时减少或避免组合物围绕容器封闭物的结垢，这导致泄漏和难以打开容器。

公开(公告)号：US20070134322A1

公开(公告)日：2007-06-14

申请号：US11610194

申请日：2006-12-13

申请人： Mahendra Dedhiya ,  Anil Chhettry ,  Yan Yang

发明人： Mahendra Dedhiya ,  Anil Chhettry ,  Yan Yang

IPC分类号： A61K9/20 ,  A61K31/343

CPC分类号： A61K9/167 ,  A61K9/1676 ,  A61K9/2018 ,  A61K9/2031 ,  A61K9/2054 ,  A61K9/209 ,  A61K9/4808 ,  A61K9/5047 ,  A61K9/5073 ,  A61K9/5078 ,  A61K9/5084 ,  A61K31/343

摘要： The present invention relates to modified and pulsatile release pharmaceutical formulations of escitalopram and their use for the treatment of central nervous system disorders, including mood disorders (e.g., major depressive disorder) and anxiety disorders (e.g., generalized anxiety disorder, social anxiety disorder, post traumatic stress disorder, and panic disorder, including panic attacks).

摘要翻译： 本发明涉及依他普仑的改进和脉动释放药物制剂及其用于治疗中枢神经系统疾病的用途，包括情绪障碍（例如重度抑郁障碍）和焦虑症（例如广泛性焦虑症，社会焦虑症，症状 创伤性应激障碍和恐慌症，包括恐慌发作）。